-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, Near Shore Protein (688137.SH) issued an announcement. The daily closing price increase deviation value of the company's stock exceeded 30% for 3 consecutive trading days on October 28, October 29, and October 30, 2026. According to the relevant provisions of the “Shanghai Stock Exchange Trading Rules” and “Real-time Monitoring Rules for Abnormal Stock Trading on the Science and Technology Innovation Board of the Shanghai Stock Exchange”, it is a situation where stock trading fluctuates abnormally. The company's AI-enabled high-throughput wet testing and data package services are still in the early stages of market expansion. As of the third quarter of 2026, related business revenue accounted for less than 2% of the company's overall revenue. Given that the application of AI in the drug development industry is still in its infancy, there are risks such as rapid technology iteration, long industry verification cycles, and difficulties in commercialization, and there is significant uncertainty about the company's future revenue and profit delivery.
Share
Listen to the news
Zhitong Finance App News, Near Shore Protein (688137.SH) issued an announcement. The daily closing price increase deviation value of the company's stock exceeded 30% for 3 consecutive trading days on October 28, October 29, and October 30, 2026. According to the relevant provisions of the “Shanghai Stock Exchange Trading Rules” and “Real-time Monitoring Rules for Abnormal Stock Trading on the Science and Technology Innovation Board of the Shanghai Stock Exchange”, it is a situation where stock trading fluctuates abnormally. The company's AI-enabled high-throughput wet testing and data package services are still in the early stages of market expansion. As of the third quarter of 2026, related business revenue accounted for less than 2% of the company's overall revenue. Given that the application of AI in the drug development industry is still in its infancy, there are risks such as rapid technology iteration, long industry verification cycles, and difficulties in commercialization, and there is significant uncertainty about the company's future revenue and profit delivery.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending